Budúce P/E spoločnosti Akari Therapeutics Plc
Aká je hodnota metriky Budúce P/E spoločnosti Akari Therapeutics Plc?
Hodnota metriky Budúce P/E spoločnosti Akari Therapeutics Plc je N/A
Aká je definícia metriky Budúce P/E?
Budúci pomer P/E (Forward price to earnings ratio) vyjadruje pomer súčasnej ceny a odhadovaného zisku na akciu za ďalších 12 mesiacov.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Čomu sa venuje spoločnosť Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.